Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NUVB
Upturn stock ratingUpturn stock rating

Nuvation Bio Inc (NUVB)

Upturn stock ratingUpturn stock rating
$1.97
Last Close (24-hour delay)
Profit since last BUY-24%
upturn advisory
SELL
SELL since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/20/2025: NUVB (1-star) is a SELL. SELL since 3 days. Profits (-24.00%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $7.17

1 Year Target Price $7.17

Analysts Price Target For last 52 week
$7.17Target price
Low$1.54
Current$1.97
high$3.97

Analysis of Past Performance

Type Stock
Historic Profit -16.43%
Avg. Invested days 37
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 656.71M USD
Price to earnings Ratio -
1Y Target Price 7.17
Price to earnings Ratio -
1Y Target Price 7.17
Volume (30-day avg) 7
Beta 1.37
52 Weeks Range 1.54 - 3.97
Updated Date 06/30/2025
52 Weeks Range 1.54 - 3.97
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.2

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1913.23%

Management Effectiveness

Return on Assets (TTM) -23.33%
Return on Equity (TTM) -119.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 206444543
Price to Sales(TTM) 59.94
Enterprise Value 206444543
Price to Sales(TTM) 59.94
Enterprise Value to Revenue 18.84
Enterprise Value to EBITDA 2.23
Shares Outstanding 339263008
Shares Floating 229037814
Shares Outstanding 339263008
Shares Floating 229037814
Percent Insiders 19.14
Percent Institutions 61.81

Analyst Ratings

Rating 3
Target Price 7.17
Buy 3
Strong Buy 4
Buy 3
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Nuvation Bio Inc

stock logo

Company Overview

overview logo History and Background

Nuvation Bio Inc. was founded in 2018 by David Hung, M.D. to focus on developing therapies that address unmet medical needs in oncology. It went public via a SPAC merger in early 2021.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on the discovery and development of therapeutic candidates for various types of cancer.

leadership logo Leadership and Structure

David Hung, M.D., is the founder and CEO. The company has a board of directors and a management team overseeing research, development, and clinical operations.

Top Products and Market Share

overview logo Key Offerings

  • NUV-868: A potent and selective BD2-sparing BET inhibitor being developed for advanced cancers. It is currently undergoing clinical trials. Market share is not applicable as the drug is in development. Competitors include companies developing similar BET inhibitors.
  • NUV-422: A CDK2/9 inhibitor in pre-clinical development. Market share is not applicable as the drug is in development. Competitors include companies developing similar CDK inhibitors.

Market Dynamics

industry overview logo Industry Overview

The oncology drug development industry is highly competitive and rapidly evolving, with significant unmet needs for effective cancer treatments.

Positioning

Nuvation Bio aims to differentiate itself through its focus on specific drug targets and its experienced leadership team.

Total Addressable Market (TAM)

The global oncology market is estimated to reach hundreds of billions of dollars. Nuvation Bio is positioned to capture a portion of this TAM by developing innovative cancer therapies.

Upturn SWOT Analysis

Strengths

  • Experienced leadership team
  • Potentially differentiated drug candidates
  • Strong focus on oncology

Weaknesses

  • Early-stage development pipeline
  • High cash burn rate
  • Dependence on clinical trial success

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion of the pipeline through acquisitions or in-licensing

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • ARRY
  • GILD

Competitive Landscape

Nuvation Bio competes with both large pharmaceutical companies and smaller biotech firms in the oncology space. Its success depends on the differentiation and effectiveness of its drug candidates.

Growth Trajectory and Initiatives

Historical Growth: The company's growth has been primarily in terms of expanding its pipeline and advancing its clinical programs.

Future Projections: Future growth is dependent on clinical trial success and potential regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success.

Recent Initiatives: Advancing clinical trials for NUV-868 and preclinical developments for NUV-422.

Summary

Nuvation Bio is a clinical-stage company with promising drug candidates in oncology. Its strengths lie in its experienced leadership and focused approach. However, it faces risks associated with clinical trial outcomes and competition from larger players. The company needs to focus on de-risking its pipeline and securing partnerships to enhance its long-term prospects.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Press releases

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Nuvation Bio Inc

Exchange NYSE
Headquaters New York, NY, United States
IPO Launch date 2020-08-24
Founder, President, CEO & Chairman Dr. David T. Hung M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 273
Full time employees 273

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.